Company intelligence / Profile preview

Akashi Therapeutics

Cambridge, Massachusetts, United Statesakashirx.com ↗

Ownership: Private
Employees: ~5
Development stage: Phase 1

Overview

Akashi’s lead candidate HT-100 demonstrated promising anti-fibrotic and muscle-regenerative effects in early-stage trials for Duchenne muscular dystrophy, with favorable safety data at lower doses. However, the program was halted after a serious adverse event at the highest dose cohort; subsequent discussions with the FDA allowed resumption of development at lower doses. Additional candidates include DT‑200 and AT‑300 for DMD.

Therapeutic areas: OtherRare Diseases
Modalities: Small molecules (HT-100/halofuginone)Selective Androgen Receptor Modulator (SARM; DT-200)Cation channel modulator (AT-300)
Industry: Biotech

Drug pipeline

1 asset

GsMTx4

Preclinical

Partnerships

Collaboration with patient advocacy organizations such as CureDuchenneseeking additional investors/development partners

Beyond the preview

Go deeper on Akashi Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Akashi Therapeutics.